Details of Disease

Disease Name

Ovarian serous cystadenocarcinoma

ovarian serous cystadenocarcinoma

Definition

A malignant serous cystic epithelial neoplasm arising from the ovary. It is characterized by the presence of glandular, papillary, or solid structures. Psammoma bodies may be present. In well differentiated cases the malignant epithelial cells resemble the cells of fallopian tube epithelium. In poorly differentiated cases the malignant epithelial cells show anaplastic features.

Disease Hierarchy

DISSU72Z: Ovarian serous adenocarcinoma

DIS6AGJI: Ovarian cystadenocarcinoma

DISVK716: Serous cystadenocarcinoma

DISMYAWR: Ovarian serous cystadenocarcinoma

Disease Identifiers

MONDO ID

MONDO_0006046

UMLS CUI

C0279663

MedGen ID

83541

General Information of Disease (ID: DISMYAWR)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Carboplatin	DMG281S	Approved	Small molecular drug	[1]
Metformin	DM89QE1	Approved	Small molecular drug	[2]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
B2M	TTY7FKA	Strong	Genetic Variation	[4]
FBXW7	TT29KY7	Strong	Genetic Variation	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GSTM5	OTMMBFY8	Strong	Biomarker	[5]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[4]
TMEM14A	OTANQA6G	Strong	Altered Expression	[6]
------------------------------------------------------------------------------------

References

1	Carboplatin FDA Label
2	Metformin FDA Label
3	Paclitaxel FDA Label
4	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
5	A comprehensive understanding of ovarian carcinoma survival prognosis by novel biomarkers.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8257-8264. doi: 10.26355/eurrev_201910_19136.
6	Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells.Biosci Rep. 2016 Feb 19;36(1):e00298. doi: 10.1042/BSR20150258. Print 2016.